Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Cytomegalovirus Infection and Guillain-Barre Syndrome: The First Case-Control Study in Iran Publisher



Mamishi S1, 2 ; Ashrafi MR1 ; Mohammadi M1 ; Zamani G1 ; Pourakbari B2 ; Mahmoudi S2 ; Azizahari S1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Pediatric Center of Excellence, Children’s Medical Center, Tehran University Medical Science, Tehran, Iran
  2. 2. Pediatric infectious Research Center, Tehran University Medical Science, Tehran, Iran

Source: Iranian Journal of Child Neurology Published:2021


Abstract

Objectives Guillain-Barre syndrome (GBS) is an immune-mediated disease of the peripheral nervous system affecting all age groups around the world. Although the pathogenesis and optimal treatment of GBS have not yet been completely identified, one of the most common infectious diseases to trigger the syndrome is cytomegalovirus (CMV) infection. The GBS following CMV infection is rarely reported in childhood, and there have been no data on GBS with antecedent CMV infection in children in Iran. The current study aimed to evaluate the association between CMV infection and GBS in children in Iran. Materials & Methods The case-control study design was used for 30 GBS cases and 30 matched controls. All the serum samples were tested for the presence of anti-CMV immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies using a commercially available enzyme-linked immunosorbent assay (EUROIMMUN Medizinische, Germany). The CMV viral deoxyribonucleic acid (DNA) in the specimen was detected using polymerase chain reaction (PCR) (Cytomegalovirus PCR Detection Kit, CinnaGen Co., Iran). Results Anti-CMV IgG antibodies were detected in 97% of the GBS patients and 93% of the healthy controls. Anti-CMV IgM antibodies were demonstrated in 33% of the healthy controls (n=10) and 33% of the GBS children (n=10). The borderline level of anti-CMV IgM antibodies was observed in 23% of the healthy controls (n=7) and 13% of the GBS children (n=4) (P=0.57). None of the specimens from both controls and GBS cases was positive for CMV DNA using PCR. Conclusion The obtained data demonstrated the presence of anti-CMV antibodies in the majority of both GBS patients and controls. Moreover, no relation was observed between CMV infection and GBS. However, it is highly recommended to perform further studies with a large sample size. © 2021, Iranian Child Neurology Society. All rights reserved.
Related Docs
1. Biological Drugs in Guillain-Barre Syndrome: An Update, Current Neuropharmacology (2017)
2. Autoimmune Diseases, Clinical Immunology (2022)
Experts (# of related papers)